CTOs on the Move

A2 Biotherapeutics

www.a2bio.com

 
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

A2 Biotherapeutics raised $57M on 11/05/2019
A2 Biotherapeutics raised $71.5M on 10/06/2020

Similar Companies

La Casa Assisted Living

La Casa Assisted Living is a Merritt Island, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anox Kaldnes Inc

Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DEKA Research and Development Corporation

DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAIC-Frederick

SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Castle Creek Biosciences

Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. The company`s proprietary autologous fibroblast platform potentially allows for the development of personalized, targeted and redosable cell-based gene therapy product candidates for monogenic and chronic disorders. The company`s most advanced product candidate, dabocemagene autoficel (D-Fi), is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds due to recessive dystrophic epidermolysis bullosa (RDEB). The company is also currently evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma. In addition, Castle Creek Biosciences is pursuing discovery and potential development of early-stage novel product candidates with the goal of expanding its robust pipeline into other rare diseases and broader indications where there are significant unmet needs. The company operates an in-house, commercial-scale manufacturing facility in Exton, Pennsylvania that benefits from the validated systems and processes previously implemented at the site for manufacture of an FDA-approved cell therapy product. Castle Creek Biosciences, Inc. is a portfolio company of Paragon Biosciences, LLC.